LAUSR

Strategic initiatives in pharmaceutical companies and drug research have incorporated the pharmacokinetics (PK) and pharmacodynamics (PD) modeling, known as the PK/PD framework. Herein, we use an inverse optimal impulsive approach to devise PK/PD-based treatment policies for infectious diseases such as HIV and influenza. The optimal PK/PDbased HIV therapy maintains the viral load under detection levels for a thirty-year period when the treatment initiates 2 or 4 years post-infection. We also explore the implications of late HIV treatment initiation. On the other hand, the optimal PK/PD-based influenza treatment reduces ca. 30% the amount of drug compared to the treatment recommended by the Food and Drug Administration while reaching the same efficacy levels (98%). The PK/PD framework mastermind new schemes for tailoring treatments in infectious diseases.